Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin‐Like Receptors (KIR) Types on Heparin‐Induced Thrombocytopenia (HIT)
Open Access
- 8 July 2017
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (9) , 1164-1171
Abstract
Heparin‐induced thrombocytopenia (HIT) is an unpredictable, life‐threatening, immune‐mediated reaction to heparin. Variation in human leukocyte antigen (HLA) genes is now used to prevent immune‐mediated adverse drug reactions. Combinations of HLA alleles and killer cell immunoglobulin‐like receptors (KIR) are associated with multiple autoimmune diseases and infections. The objective of this study is to evaluate the association of HLA alleles and KIR types, alone or in the presence of different HLA ligands, with HIT. HIT cases and heparin‐exposed controls were identified in BioVU, an electronic health record coupled to a DNA biobank. HLA sequencing and KIR type imputation using Illumina OMNI‐Quad data were performed. Odds ratios for HLA alleles and KIR types and HLA*KIR interactions using conditional logistic regressions were determined in the overall population and by race/ethnicity. Analysis was restricted to KIR types and HLA alleles with a frequency greater than 0.01. The p values for HLA and KIR association were corrected by using a false discovery rate qHLA‐DRB3*01:01 allele was significantly associated with HIT in the overall population (odds ratio 2.81 [1.57–5.02], p=2.1×10−4, q=0.02) and in individuals with European ancestry, independent of other alleles. No KIR types were associated with HIT, although a significant interaction was observed between KIR2DS5 and the HLA‐C1 KIR binding group (p=0.03). The HLA‐DRB3*01:01 allele was identified as a potential risk factor for HIT. This class II HLA gene and allele represent biologically plausible candidates for influencing HIT pathogenesis. We found limited evidence of the role of KIR types in HIT pathogenesis. Replication and further study of the HLA‐DRB3*01:01 association is necessary.Keywords
Funding Information
- National Center for Advancing Translational Sciences (ULTR000445, UL1TR000445)
- National Institute of General Medical Sciences (RC2GM092618)
- National Human Genome Research Institute (U01HG004603, U19HL065962)
- American Heart Association (16SDG29090005, 15POST22660017)
- American College of Clinical Pharmacy Research Institute
This publication has 40 references indexed in Scilit:
- Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second editionBritish Journal of Haematology, 2012
- Treatment and Prevention of Heparin-Induced ThrombocytopeniaChest, 2012
- Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data qualityGenetic Epidemiology, 2011
- Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentAIDS, 2011
- Evaluation of a Method to Identify and Categorize Section Headers in Clinical DocumentsJournal of the American Medical Informatics Association, 2009
- Identifying QT prolongation from ECG impressions using a general-purpose Natural Language ProcessorInternational Journal of Medical Informatics, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- Principal components analysis corrects for stratification in genome-wide association studiesNature Genetics, 2006
- HLA-DRw52a is involved in alloimmunization against PL-A1 antigenHuman Immunology, 1990